Dr. Frederick H. Hausheer has been appointed chief medical officer, WuXi AppTec. Dr. Hausheer will provide medical, scientific and operational leadership to WuXi Clinical operations in the U.S., China and other territories. He will also play a key role in forging and maintaining connections between customers and WuXi’s business units by providing input on medical and clinical development strategies for integrating from preclinical translational research and development into first-in-human studies, as well as for Phase I-IV development plans.

Dr. Hausheer brings more than 30 years of experience in global oncology clinical drug development and translational science and medicine in commercial and academic settings. He has extensive experience in translational/IND programs, clinical trial design, commercial clinical development, and involvement in regulatory interactions for novel agents spanning from pre-IND and Phase I-III development in the United States, China, Europe, Japan and other territories.

“We’re very excited to welcome Dr. Hausheer onboard as our Chief Medical Officer,” said Mr. Edward Hu, Co-CEO of WuXi AppTec. “Dr. Hausheer’s rich experience in global oncology clinical drug development and translational science and medicine makes him ideally suited to taking this role. We are confident in his leadership to strengthen WuXi’s clinical development capabilities and capacity globally, and enable more customers to develop better medicine faster to benefit patients around the world.”

Prior to joining WuXi, Dr. Hausheer held chief executive and chief medical positions with several biopharma companies, and was the founder and chairman of BioNumerik Pharmaceuticals. He has also served as a business advisory board member to JP Morgan Chase, the Whittaker Institute at Johns Hopkins, and the National Cancer Institute.